SFO
OVID icon

Stokes Family Office’s Ovid Therapeutics OVID Stock Holding History

Stokes Family Office’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,246
Closed -$48K – 287
2022
Q1 		$48K Buy
+15,246
New +$48K 0.01% 256

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Stokes Family Office's OVID Position: Q2 2022 in Review

Stokes Family Office sold out of Ovid Therapeutics (OVID) in Q2 2022, closing a stake of 15,246 shares — an estimated $48K sold.

Stokes Family Office first reported a position in OVID in Q1 2022 and held it in 1 quarter. The position peaked at $48K in Q1 2022. 55 funds tracked by Wall St. Rank hold OVID as of Q2 2022.

  • Stokes Family Office reported no remaining Ovid Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Stokes Family Office sold 15,246 Ovid Therapeutics shares in Q2 2022, an estimated $48K.
  • Stokes Family Office first reported a position in Ovid Therapeutics in Q1 2022 and held it in 1 quarter.
  • Stokes Family Office's Ovid Therapeutics position peaked at $48K in Q1 2022.
  • 55 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2022.

Based on Stokes Family Office's 13F filing for Q2 2022, filed 5 Aug 2022.